MPR Launches Global CRO Strategic Alliance
To expand the scale and scope of its operations, MPR announced the launch of a development group embracing its global strategic alliance with additional four CRO’s in India, South America, Russia, and Central Europe.
This move expands the company’s capabilities in early phase clinical research in India and Argentina, central lab capabilities in Russia, and increases the number of countries to support clinical research with additional five major countries in South America and Eastern Europe.
The Strategic Alliance initiative intends to combine the resources of the participating companies leading to potentially merging some or all of these companies’ assets. The terms of the alliances contracts are flexible. This initiative will optimize delivery, increase efficiency and reduce costs of services provided by the Company.
The CRO business of the Company will be rebranded as MPR Development Group. Plans to spin off CRO business under this name and to set up an independent company structure are contemplated by the Board of Directors of the Company in coordination with few professional investors.
The four CRO’s joining the MPR CRO Alliance are: ACCELL Clinical Research (Russia and Ukraine), Cromos Pharma (USA based CEE CRO), Fortis Clinical Research (India), and Research Development RA. S.A. (South America),
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
